Ulcerative Colitis

This presentation provides an in-depth overview of Ulcerative Colitis (UC)—a chronic idiopathic inflammatory bowel disease characterized by continuous mucosal inflammation of the colon and rectum. It explores the epidemiology, genetic predispositions, environmental and microbial risk factors, and the underlying immunopathogenesis, including dysregulated T-cell responses, cytokine imbalance, epithelial barrier dysfunction, and alterations of the gut microbiome. Extraintestinal manifestations such as arthritis, skin and liver disorders, and systemic complications are also addressed.

Diagnostic strategies encompass colonoscopy with biopsy, imaging modalities, and biomarkers such as fecal calprotectin, while conventional management includes aminosalicylates, corticosteroids, immunomodulators, biologic therapies, and surgical intervention in refractory cases. Moving beyond standard approaches, the presentation introduces advanced regenerative and integrative solutions, including Precursor Stem Cell Therapy (PSCT), Autologous Active Specific Immunotherapy (AASI®), Nano Organo Peptides (NOP) Thymus and Mito Organelle (MO) Thymus for Thymus Therapy, Nano Organo Peptides (NOP) Super Transfer Factor (STF), Mito Organelles (MO) Super Transfer Factor (STF), and GcMAF Forte. Anchored in scientific literature and enriched with clinical case insights, this program is designed for gastroenterologists, immunologists, and healthcare professionals seeking to advance their expertise in the pathophysiology and innovative management of Ulcerative Colitis.